Gastroparesis Management

1. Confirm the diagnosis and address contributing factors

• Diagnosis requires a 4-hour gastric emptying scintigraphy study (2025 AGA guideline recommends against shorter 2-hour testing). Retention at 4 hours: 10-15% = mild, 15-35% = moderate, >35% = severe (Yamada's Textbook of Gastroenterology, p. 2557-2560; Sabiston Textbook of Surgery).
• Stop or minimize motility-impairing drugs: opioids, GLP-1 receptor agonists/analogs, calcium channel blockers, tricyclic antidepressants, and dopamine agonists (Sabiston; Yamada's).
• Optimize glycemic control in diabetic gastroparesis - hyperglycemia itself worsens antral contractility and suppresses the migrating motor complex (Sabiston Textbook of Surgery, p. 1861-1875).

2. Dietary/first-line conservative therapy

• Small, frequent meals, low in fat and insoluble fiber; avoid acidic/spicy foods.
• A blenderized/small-particle diet as needed for mild-moderate disease, and routinely for severe disease.
• Liquid diet if solids aren't tolerated; correct dehydration, electrolyte, and vitamin deficiencies.
• Nutritional support: caloric liquids for moderate/severe disease; enteral (jejunostomy) or parenteral nutrition reserved for severe disease with malnutrition, generally preceded by an NG decompression/nasojejunal feeding trial (Sabiston, p. 1875-1879; Yamada's, p. 2560).

3. Pharmacologic therapy (for persistent symptoms)

4. Refractory disease - endoscopic/surgical options

• Gastric per-oral endoscopic pyloromyotomy (G-POEM) - increasingly used; a sham-controlled RCT was stopped early for benefit in severe gastroparesis.
• Gastric electrical stimulation (GES) - FDA humanitarian device exemption for refractory diabetic/idiopathic gastroparesis; benefit greater in open-label than blinded trials.
• Pyloric botulinum toxin injection - reduces pylorospasm; efficacy data are mixed/uncontrolled.
• Surgical pyloromyotomy/pyloroplasty - AGA 2025 issued no recommendation (evidence gap), though some systematic reviews suggest benefit for nausea/pain comparable to or better than GES.
• Venting gastrostomy (symptom relief) and jejunostomy feeding tube (nutrition) for severe refractory disease.
• Gastrectomy is a last resort in highly selected, severely refractory cases.

Multidisciplinary approach

Sources

• Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice, "Treatment" (Gastroparesis), p. 1875-1883
• Yamada's Textbook of Gastroenterology, 7th ed., "Gastroparesis," p. 2555-2568
• Staller K, Parkman HP, Greer KB, et al. AGA Clinical Practice Guideline on Management of Gastroparesis. Gastroenterology. 2025;169(5):828-861. PMID: 40976635 (most current, 2025)

Gastroparesis Management in Diabetic Patients

1. Break the hyperglycemia-dysmotility cycle

• Acute hyperglycemia (>220 mg/dL) directly delays gastric emptying: it causes antral hypomotility, gastric dysrhythmias, pylorospasm, and blunts the effect of prokinetics like erythromycin. Practically, this means gastric emptying studies should be done with the patient's glucose reasonably controlled, and poor glycemic control can make gastroparesis look worse than it is (Sleisenger and Fordtran's, p. 2470; Yamada's Textbook of Gastroenterology).
• Long-term poor glycemic control drives the neuropathy underlying DGP - it typically occurs in long-standing (>10 years) diabetes with concurrent retinopathy, nephropathy, and peripheral/autonomic neuropathy, though up to 39% of diabetic gastroparesis patients have no other diabetic complications (Yamada's, p. 989-991; Sleisenger and Fordtran's, p. 962-2463).

2. The insulin-timing problem (unique to diabetics)

• Delayed gastric emptying means nutrient absorption lags behind the action of pre-meal short-acting insulin, causing unexpected postprandial hypoglycemia followed later by delayed hyperglycemia when food finally empties into the duodenum.
• Adjust insulin timing, not just dose: consider giving rapid-acting insulin during or after meals rather than pre-meal, or split dosing, to better match delayed nutrient delivery. Monitor 2-hour postprandial glucose rather than relying solely on pre-meal values (Yamada's Textbook of Gastroenterology, p. 1292).
• Prioritize minimizing glucose variability over hitting a single steady-state target - wide swings (not just mean glucose) worsen gastric motility.
• CGM + insulin pump therapy has trial evidence: the NIH GLUMIT-DG study (45 poorly controlled DGP patients, baseline A1c 9.4%) showed a 1.1% A1c reduction at 24 weeks with minimal increase in hypoglycemic events, plus improved GI symptoms and nutrient tolerance - supporting intensive CGM/pump-based regimens in this population (Yamada's, p. 1294).

3. Diabetes medications to stop or avoid

• GLP-1 receptor agonists/analogs (exenatide, liraglutide, semaglutide, tirzepatide) and amylin analogs (pramlintide) slow gastric emptying and should generally be discontinued or avoided in diabetic gastroparesis (Sleisenger and Fordtran's, p. 964; Lippincott Illustrated Reviews: Pharmacology).
• DPP-4 inhibitors do NOT delay gastric emptying and are a reasonable alternative glucose-lowering option (Sleisenger and Fordtran's, p. 964).
• Avoid other motility-slowing agents used commonly in diabetics with comorbidities: anticholinergics, calcium channel blockers, and opioids for neuropathic pain if possible.

4. Same prokinetic/antiemetic ladder, with diabetic-specific caveats

• Metoclopramide: use lowest effective dose/shortest duration - diabetic patients often have concurrent renal impairment (nephropathy), which necessitates dose reduction given risk of tardive dyskinesia/extrapyramidal effects.
• Erythromycin: tachyphylaxis limits long-term use, and its prokinetic effect is blunted by hyperglycemia, reinforcing that glucose control is a prerequisite for medical therapy to work.

5. Refractory disease - diabetic-specific option

• Pancreatic transplantation (typically simultaneous with kidney transplant in type 1 diabetics with nephropathy) has been shown to improve diabetic gastroparesis, with evidence of early enteric nerve fiber regeneration alongside improved glycemic control (Yamada's Textbook of Gastroenterology, "Pancreatic transplantation for diabetic gastroparesis," p. 1504).
• Otherwise, the same refractory pathway applies: G-POEM, gastric electrical stimulation (FDA humanitarian device exemption specifically covers refractory diabetic and idiopathic gastroparesis), pyloric botulinum toxin, and venting/feeding tubes - all per shared decision-making as in the general AGA 2025 guideline.

Bottom line for diabetics specifically

1. Optimize and stabilize glucose (minimize both hyper- and hypoglycemia, not just target A1c).
2. Reconsider insulin timing/regimen (post-meal or split dosing; consider CGM + pump).
3. Stop GLP-1 agonists/pramlintide; switch to DPP-4 inhibitors if an incretin-based agent is needed.
4. Apply standard dietary and prokinetic (metoclopramide/erythromycin) therapy, adjusting metoclopramide for renal function.
5. Consider pancreas transplant in appropriate type 1 diabetics with ESRD; otherwise follow the same refractory-disease pathway as idiopathic gastroparesis.

Sources

• Yamada's Textbook of Gastroenterology, 7th ed., "Diabetic gastroparesis," p. 987-1012, 1291-1294, 1504
• Sleisenger and Fordtran's Gastrointestinal and Liver Disease, "Diabetic Gastroparesis," p. 956-970, 2461-2470
• Lippincott Illustrated Reviews: Pharmacology - amylin analog/pramlintide contraindications
• AGA Clinical Practice Guideline on Management of Gastroparesis, Gastroenterology 2025;169(5):828-861 (PMID: 40976635) - applies to both idiopathic and diabetes-related gastroparesis